# US 2011/0217288 A1 · Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0217288 A1
- Document ID: US20110217288A1
- Status: Published application
- Kind: A1
- Application number: 13/038,293
- Filed: 2011-03-01
- Published: 2011-09-08
- Earliest claimed: 2010-03-05
- Assignees: Baylor Research Institute
- Inventors: Jinsong Shen; Raphael Schiffmann; Xingli Meng
- Web page: https://patentgrep.com/patent/US20110217288A1

## CPC

- G01N 33/743: {Steroid hormones}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 5/26: Androgens
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel therapies for the treatment of Fabry disease by using androgen/androgen receptor (AR) pathway-related molecules as biomarkers and use of approaches targeting androgen/AR pathway are presented herein. The involvement of aberrant androgen/AR pathway in Fabry disease has never been previously described. The present invention describes, (i) use of approaches that target androgen/AR pathway as therapeutic treatments for Fabry disease and (2) use of the levels of androgen/AR pathway-related molecules in body fluids or tissues as biomarkers for evaluation of disease progression and efficacy of treatments in Fabry patients.

## Claims

### Claim 1

A method of diagnosing Fabry's disease in a subject comprising the steps of:
collecting a sample from the subject suspected of having Fabry's disease;
comparing a level of one or more molecules selected from the group consisting of an androgen, an androgen precursor, an androgen metabolite, an androgen-receptor (AR) pathway molecule, and one or more AR target genes and related metabolites in the sample from the subject suspected of having Fabry's disease with that of a normal subject not having Fabry's disease; and
determining whether the subject has Fabry's disease based on a statistically significant change in the levels of the one or more molecules in the samples between the subject suspected of having Fabry's disease and the normal subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is a biological fluid sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the one or more molecules comprise testosterone, dihydrotestosterone (DHT) and precursors, congeners, salts, complexes, analogs of testosterone and DHT, insulin-like growth factor 1 (IGF-I), and Phosphorylated Akt.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method comprises a comparison of a ratio between the Phosphorylated Akt to a total Akt in the samples between the subject suspected of having Fabry's disease and the normal subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the ratio of the Phosphorylated Akt to total Akt is increased in the sample of the subject suspected of having Fabry's disease.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject suspected of having Fabry's disease may optionally show a hypertrophy of one or more organs selected from a heart, a kidney, a liver, and a spleen.

### Claim 7

A method of monitoring the efficacy of a therapeutic intervention on a patient suffering from Fabry's disease comprising the steps of:
administering one or more pharmaceutical compositions to the patient at one or more pre-defined intervals, wherein the pharmaceutical composition comprises one or more therapeutic agents against Fabry's disease;
collecting a sample from the patient;
comparing a level of one or more molecules selected from the group consisting of an androgen, an androgen precursor, an androgen metabolite, an androgen-receptor (AR) pathway molecule, and one or more AR target genes and related metabolites in the sample from the patient undergoing the therapeutic intervention with that of the same patient prior to the commencement of the therapeutic intervention; and
determining whether the therapeutic intervention is effective based on the comparison of a measured level of the one of more molecules in the sample from the patient before and after the commencement of the therapeutic intervention.

### Claim 8 (depends on 7)

The method of claim 7, wherein the sample is a biological fluid sample.

### Claim 9 (depends on 7)

The method of claim 7, further comprising the step of terminating the therapeutic intervention based on the comparison of the measured levels of the androgen, the androgen precursor, the androgen metabolite, the androgen-receptor (AR) pathway molecule, and one or more AR target genes and related metabolites before and after the commencement of the therapeutic intervention.

### Claim 10 (depends on 7)

The method of claim 7, further comprising the step of continuing the therapeutic intervention based on the comparison of the measured levels of the androgen, the androgen precursor, the androgen metabolite, the androgen-receptor (AR) pathway molecule, and AR target genes and related metabolites before and after the commencement of the therapeutic intervention.

### Claim 11 (depends on 7)

The method of claim 7, further comprising the step of modifying the therapeutic intervention based on the comparison of the measured levels of the androgen, the androgen precursor, the androgen metabolite, the androgen-receptor (AR) pathway molecule, and AR target genes and related metabolites before and after the commencement of the therapeutic intervention, wherein the modification comprises an increase or a decrease in a dosage, a frequency or both of the one or more pharmaceutical compositions or combinations thereof.

### Claim 12 (depends on 7)

The method of claim 7, wherein the one or more molecules comprise testosterone, dihydrotestosterone (DHT) and precursors, congeners, salts, complexes, analogs of testosterone and DHT, insulin-like growth factor 1 (IGF-I), and Phosphorylated Akt.

### Claim 13 (depends on 7)

The method of claim 7, wherein a decreased level of the IGF-I, the Phosphorylated Akt or both in the sample of the patient after the commencement of the therapeutic intervention is indicative of a successful therapeutic intervention.

### Claim 14 (depends on 7)

The method of claim 7, wherein the method comprises a measurement of a ratio between the Phosphorylated Akt to a total Akt in the sample of the patient before and after the commencement of the therapeutic intervention.

### Claim 15 (depends on 14)

The method of claim 14, wherein a decrease in the ratio of the Phosphorylated Akt to total Akt is indicative of the successful therapeutic intervention.

### Claim 16 (depends on 7)

The method of claim 7, wherein the therapeutic intervention comprises medical or surgical castration, androgen synthesis blockers, 5α-reductase enzyme inhibitors, AR gene expression knockdown agents, inhibitors of HSP90, AR pathway kinase blocking agents, enzyme replacement therapies, histone deacetylases inhibitors, pain medications, dialysis, organ transplantation, diet modifications or any combinations thereof.

### Claim 17

A pharmaceutical composition for treating Fabry's disease in a patient comprising:
a therapeutically effective amount of at least one of an androgen synthesis blocker, a 5α-reductase enzyme inhibitors, an androgen-receptor (AR) gene expression knockdown agent, an inhibitor of HSP90, an AR pathway kinase blocking agents or a histone deacetylases inhibitors sufficient to treat Fabry's disease dissolved, dispersed or suspended in an aqueous or a non-aqueous solvent;
one or more optional related co-factors, proteins, antibodies, pain medications, and other pharmaceutically active agents dissolved, dispersed, or suspended in an aqueous or a non-aqueous solvent; and
one or more optional excipients, fillers, diluents, extended or controlled release agents, bulking agents, antiadherents, binders, lubricants, preservatives or any combinations thereof.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the pharmaceutical composition comprises antiandrogens, flutamide, cyproterone acetate, ketoconazole, spironolactone, finasteride, geldanamycin and related analogues and derivatives, valproic acid, suberoylanilide hydroxamic acid (SAHA), Romidespin, (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, N-(2-Aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide or any combinations thereof.

### Claim 19 (depends on 17)

The composition of claim 17, wherein the pharmaceutical composition is infused, administered subcutaneously, intravenously, peritoneally, orally, and intramuscularly.

### Claim 20 (depends on 17)

The composition of claim 17, wherein the composition decreases a level insulin-like growth factor 1 (IGF-I), and Phosphorylated Akt in a biological sample of the patient taking the pharmaceutical composition when compared to the sample of the patient not taking the pharmaceutical composition.

### Claim 21 (depends on 17)

The composition of claim 17, wherein the composition decreases a ratio of the Phosphorylated Akt to total Akt in the biological sample of the patient taking the pharmaceutical composition when compared to the sample of the patient not taking the pharmaceutical composition.

### Claim 22

A method of treating Fabry's disease in one or more subjects comprising the steps of:
identifying the one or more subjects in need of treatment against Fabry's disease; and
administering one or more pharmaceutical compositions comprising a therapeutically effective amount at least one of an androgen synthesis blocker, a 5α-reductase enzyme inhibitors, an androgen-receptor (AR) gene expression knockdown agent, an inhibitor of HSP90, an AR pathway kinase blocking agents or a histone deacetylases inhibitors sufficient to treat Fabry's disease.

### Claim 23 (depends on 22)

The method of claim 22, further comprising the steps of monitoring the progression of Fabry's disease following the administration of the pharmaceutical composition, wherein the monitoring comprises measuring a level of at least one of an insulin-like growth factor 1 (IGF-I), a Phosphorylated Akt, and a ratio of the Phosphorylated Akt to total Akt following treatment and comparing the measured levels with the measured levels prior to the treatment.

### Claim 24 (depends on 22)

The method of claim 22, further comprising the step of terminating, continuing or modifying the treatment based on the levels of the insulin-like growth factor 1 (IGF-I), the Phosphorylated Akt, and the ratio of the Phosphorylated Akt to total Akt before and after the commencement of the treatment, wherein the modification comprises an increase or a decrease in a dosage, a frequency or both of the one or more pharmaceutical compositions or combinations thereof.

### Claim 25 (depends on 22)

The method of claim 22, wherein the pharmaceutical composition comprises antiandrogens, flutamide, cyproterone acetate, ketoconazole, spironolactone, finasteride, geldanamycin and related analogues and derivatives, valproic acid, suberoylanilide hydroxamic acid (SAHA), Romidespin, (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, N-(2-Aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide or any combinations thereof.

### Claim 26 (depends on 22)

The method of claim 22, wherein the pharmaceutical composition is infused, administered subcutaneously, intravenously, peritoneally, orally, and intramuscularly.

### Claim 27

A method of treating Fabry's disease in one or more subjects comprising the steps of:
identifying the one or more subjects in need of treatment against Fabry's disease; and
performing a surgical or a medical castration on the subject in need of treatment against the Fabry's disease.

### Claim 28 (depends on 27)

The method of claim 27, further comprising the steps of monitoring the progression of Fabry's disease following the surgical or medical castration, wherein the monitoring comprises measuring a level of at least one of an insulin-like growth factor 1 (IGF-I), a Phosphorylated Akt, and a ratio of the Phosphorylated Akt to total Akt following the castration treatment and comparing the measured levels with the measured levels prior to the castration.

### Claim 29 (depends on 27)

The method of claim 27, wherein a decreased level of the IGF-I, the Phosphorylated Akt or both in the sample of the patient after the castration is indicative of a successful treatment.

### Claim 30 (depends on 27)

The method of claim 27, wherein a decrease in the ratio of the Phosphorylated Akt to total Akt after the castration is indicative of the successful treatment.
